small molecule

AMLODIPINE BENZOATE

AMLODIPINE BENZOATE

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameAMLODIPINE BENZOATE
Active ingredientAMLODIPINE BENZOATE
StrengthEQ 1MG BASE/ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalJune 2023
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.